Press Releases and News

RedShiftBio Expands Team to Support Demand for AQS3™pro Read more>

RedShiftBio’s  AQS3™pro: Finalist in The Prism Awards 2019 Read more>

RedShiftBio’s AQS3pro Wins a ‘The Analytical Scientist Innovation Award’ (TASIA) 2018 Read more>

RedShiftBio to showcase successful studies with biopharma industry leaders at AAPS PharmSci 360 Read more>

Biopharm International interviews scientists with experience of Microfluidic Modulation Spectroscopy for a round-table on how complex protein studies demand dynamic techniques. Visit page 18 to see what Immunogen, Janssen, Elion Labs and the University of Delaware have to say. Read more>

American Pharmaceutical Review publishes article on MMS by Karan K. Shah Principal Development Associate Analytical and Pharmaceutical Sciences ImmunoGen, Inc. Read more>

RedShiftBio Strengthens Focus on Applications with New Hire Read more>

Spectroscopy North America publishes peer-reviewed paper on MMS from Brent Kendrick of Elion Labs, Eugene Ma and Libo Wang of RedShiftBio Read more>

RedShiftBio Expands Team to Support Launch of FlagShip AQS3™pro System for Protein Characterization Read more>

Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS3pro Read more>

Spectroscopy Europe highlights the launch of the AQS3pro Read more>

RedShiftBio Launches AQS3pro Protein Characterization System Read more>

RedShiftBio Announces Collaboration Trial Completion Read more>

Jeffrey Zonderman Joins RedShiftBio as its Chief Commercial Officer Read more >

RedShiftBio Inc. Completes $11.0 million Series C Financing Read more >

RedShiftBio™

RedShiftBio™ is an innovative provider of analytical instrumentation for the research, development and manufacturing of protein therapeutic drugs.

Read More

Awards

TAS-footer
prism-logo-footer

Contact Us

RedShift BioAnalytics Inc.

131 Middlesex Turnpike
Burlington, MA 01803

T: 781.345.7300
F: 781-345-7301
E: info@redshiftbio.com

RedShift™, RedShiftBio™,  See Change™, and AQS3™ are trademarks of RedShift BioAnalytics, Inc.